Multiple System Atrophy (MSA) https://greenmedinfo.com/taxonomy/term/76348/all en Gluten ataxia may be the single most common cause of sporadic idiopathic ataxia. https://greenmedinfo.com/article/gluten-ataxia-may-be-single-most-common-cause-sporadic-idiopathic-ataxia PMID:  Brain. 2003 Mar;126(Pt 3):685-91. PMID: 12566288 Abstract Title:  Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. Abstract:  We previously have described a group of patients with gluten sensitivity presenting with ataxia (gluten ataxia) and suggested that this disease entity may account for a large number of patients with sporadic idiopathic ataxia. We have therefore investigated the prevalence of gluten sensitivity amongst a large cohort of patients with sporadic and familial ataxia and looked at possible genetic predisposition to gluten sensitivity amongst these groups. Two hundred and twenty-four patients with various causes of ataxia from North Trent (59 familial and/or positive testing for spinocerebellar ataxias 1, 2, 3, 6 and 7, and Friedreich's ataxia, 132 sporadic idiopathic and 33 clinically probable cerebellar variant of multiple system atrophy MSA-C) and 44 patients with sporadic idiopathic ataxia from The Institute of Neurology, London, were screened for the presence of antigliadin antibodies. A total of 1200 volunteers were screened as normal controls. The prevalence of antigliadin antibodies in the familial group was eight out of 59 (14%), 54 out of 132 (41%) in the sporadic idiopathic group, five out of 33 (15%) in the MSA-C group and 149 out of 1200 (12%) in the normal controls. The prevalence in the sporadic idiopathic group from London was 14 out of 44 (32%). The difference in prevalence between the idiopathic sporadic groups and the other groups was highly significant (P<0.0001 and P<0.003, respectively). The clinical characteristics of 68 patients with gluten ataxia were as follows: the mean age at onset of the ataxia was 48 years (range 14-81 years) with a mean duration of the ataxia of 9.7 years (range 1-40 years). Ocular signs were observed in 84% and dysarthria in 66%. Upper limb ataxia was evident in 75%, lower limb ataxia in 90% and gait ataxia in 100% of patients. Gastrointestinal symptoms were present in only 13%. MRI revealed atrophy of the cerebellum in 79% and white matter hyperintensities in 19%. Forty-five percent of patients had neurophysiological evidence of a sensorimotor axonal neuropathy. Gluten-sensitive enteropathy was found in 24%. HLA DQ2 was present in 72% of patients. Gluten ataxia is therefore the single most common cause of sporadic idiopathic ataxia. Antigliadin antibody testing is essential at first presentation of patients with sporadic ataxia. https://greenmedinfo.com/article/gluten-ataxia-may-be-single-most-common-cause-sporadic-idiopathic-ataxia#comments Ataxia: Idiopathic Celiac Disease Gluten Sensitivity Multiple System Atrophy Multiple System Atrophy (MSA) Human Study Fri, 05 Nov 2010 22:18:51 +0000 greenmedinfo 58421 at https://greenmedinfo.com It has been suggested that EGCG may have therapeutic value in patients with MSA; the theory must still be tested. https://greenmedinfo.com/article/it-has-been-suggested-egcg-may-have-therapeutic-value-patients-msa-theory-must PMID:  J Neural Transm (Vienna). 2016 Apr ;123(4):439-45. Epub 2016 Jan 25. PMID: 26809243 Abstract Title:  The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. Abstract:  Formation of toxicα-synuclein oligomers appears to be a key underlying pathological mechanism of synucleinopathies such as Parkinson's disease or multiple system atrophy (MSA). Given that Epigallocatechin-gallate has been shown to inhibit α-synuclein aggregation, it might represent a causal treatment option. Therefore, we set out to evaluate the safety, tolerability and a potential disease-modifying effect of Epigallocatechin-gallate in patients with MSA after 48 weeks of treatment. Power calculation was performed on existing natural history data on the progression of the Unified MSA Rating Scale as primary readout parameter. To assess the efficacy of Epigallocatechin-gallate versus placebo regarding the reduction of disease progression measured during the study period (80 % power, 5 % p level, 50 % effect size) 36 patients per group are needed. Considering a drop-out rate of 20 % a total of 86 patientswill be recruited in this multicentre study. These data provide a solid rationale to investigate whether supplementation of Epigallocatechin-gallate can delay the progression of the MSA-related disability. https://greenmedinfo.com/article/it-has-been-suggested-egcg-may-have-therapeutic-value-patients-msa-theory-must#comments EGCG (Epigallocatechin gallate) Multiple System Atrophy (MSA) Commentary Wed, 27 Jul 2016 22:36:28 +0000 greenmedinfo 131162 at https://greenmedinfo.com Moxibustion, an alternative therapy, has discernable value in multiple system atrophy patients. https://greenmedinfo.com/article/moxibustion-alternative-therapy-has-discernable-value-multiple-system-atrophy- PMID:  Intern Med. 2007 ;46(13):1015-8. Epub 2007 Jul 2. PMID: 17603243 Abstract Title:  Moxibustion, an alternative therapy, ameliorated disturbed circadian rhythm of plasma arginine vasopressin and urine output in multiple system atrophy. Abstract:  Previously no alternative therapy approach has been made to ameliorate disturbed circadian arginine vasopressin rhythm (C-AVP-R) in multiple system atrophy (MSA). A 65-year-old man with MSA showed loss of C-AVP-R and nocturnal polyuria. We performed moxibustion at specific acupuncture points on the bladder and inside the feet, once a day, 3 times a week, for 6 months. After the treatment, his C-AVP-R appeared to be normal, and the nocturnal urine output decreased to 75% (p<0.01). Together with the previous studies, it seems possible that somatic warm stimulation by moxibustion in specific points might have facilitated AVP secretion in this patient. https://greenmedinfo.com/article/moxibustion-alternative-therapy-has-discernable-value-multiple-system-atrophy-#comments Multiple System Atrophy (MSA) Moxibustion Human Study Wed, 27 Jul 2016 22:41:37 +0000 greenmedinfo 131168 at https://greenmedinfo.com Yisui decoction plus western medicine improves clinical symptoms of multiple system atrophy patients. https://greenmedinfo.com/article/yisui-decoction-plus-western-medicine-improves-clinical-symptoms-multiple-syst PMID:  Zhongguo Zhong Yao Za Zhi. 2014 Aug ;39(15):2968-71. PMID: 25507564 Abstract Title:  [Clinical effect of Yisui decoction plus western medicine in treating multiple system atrophy]. Abstract:  To observe the clinical effect of Yisui decoction plus western medicine in treating multiple system atrophy patients, totally 65 patients from China-Japan Friendship hospital during 2008-2012 with complete clinical data and received consecutive traditional Chinese medicine and western medicine treatment for more than 3 months were observed changes of traditional Chinese medicine symptom score, part 1 of unified multiple system atrophy rating scale, orthostatic hypotension before treatment and after 3 months treatment. After 3 months treatment, total effective rate of traditional Chinese medicine symptom was 70.8%. Compared with before treatment, score of part 1 of unified multiple system atrophy rating scale was obviously reduced after 3 month treatment (P https://greenmedinfo.com/article/yisui-decoction-plus-western-medicine-improves-clinical-symptoms-multiple-syst#comments Chinese Herbal Formula: Yisui decoction Multiple System Atrophy (MSA) Human Study Wed, 27 Jul 2016 22:39:32 +0000 greenmedinfo 131166 at https://greenmedinfo.com